DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Wolfgang Rattay - 1 Evan Seigerman - 1 BioNTech - 1 Albert Bourla - 1 Angela Hwang - 1 Paxlovid - 1 Bhanvi Satija - 1 Michael Erman - 1
Top related locs:
Europe Paxlovid Bengaluru New York
Top related orgs:
REUTERS - 1 Pfizer - 1 BMO Capital - 1 Reuters Graphics Pfizer - 1 GSK - 1 CVS - 1 Analysts - 1 U.S . - 1

Search resuls for: "Angela Hwang"


3 mentions found


☆ Pfizer looks beyond COVID after quarterly loss on Paxlovid charge
  + stars: | 2023-10-31 | by ( Bhanvi Satija Michael Erman | Bhanvi Satija | Michael Erman | ) www.reuters.com   time to read: +4 min
Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022. Sales of Paxlovid and the vaccine Pfizer makes with German partner BioNTech (22UAy.DE) had boosted revenue to record levels the last two years. Reuters GraphicsPfizer continues to expect 2023 revenue growth of 6%-8% from non-COVID products, with a majority occurring in the second half. Paxlovid sales slumped 97% in the third quarter to $202 million, while vaccine revenue of $1.31 billion was down from $4.4 billion a year earlier. Analysts had expected $1.44 billion for the vaccine and $618.20 million from Paxlovid, according to LSEG data.
Persons: Wolfgang Rattay, Evan Seigerman, BioNTech, Albert Bourla, Angela Hwang, Paxlovid, Bhanvi Satija, Michael Erman, Sriraj Kalluvila, Bill Berkrot Organizations: REUTERS, Pfizer, BMO Capital, Reuters Graphics Pfizer, GSK, CVS, Analysts, U.S ., Thomson Locations: Europe, Paxlovid, Bengaluru, New York
☆ A new migraine medication is coming this summer — and it promises relief in just 15 minutes
  + stars: | 2023-03-11 | by ( Aidan Pollard | ) www.businessinsider.com   time to read: +2 min
The Food and Drug Administration on Friday approved a new nasal spray to treat migraines. The spray will be available in July and is designed to treat migraines in 15 minutes. The drug, which Pfizer acquired when it bought out Biohaven Pharmaceuticals last year for $11.6 billion, will provide an alternative to oral migraine medication, NBC News reported. The drug is not the first nasal medication of its kind, but it's anticipated to work more rapidly — the medication is intended to offer relief within 15 minutes, according to Pfizer. "Among my migraine patients, one of the most important attributes of an acute treatment option is how quickly it works."
☆ Pfizer developed the Covid vaccine with most of its workforce logging in from home – but a company executive says it's time for employees to get back to the office
  + stars: | 2022-10-13 | by ( Samantha Delouya | ) www.businessinsider.com   time to read: +3 min
Nearly 2 years after developing a vaccine, Pfizer's Angela Hwang said in-person work is essential for workplace culture. Though many worked from home developing the vaccine, Pfizer's culture was "banked" from years of in-person work, she said. Some companies have recently faced backlash for requiring in-person work. Now, nearly two years after Pfizer and other drugmakers introduced effective vaccines against the virus, requiring workers to return to the office doesn't seem as far-fetched. "Remote working is effective for certain kinds of work," she said.
0 next >>
Total: 3